Evidence map›Paper›PMID 35884047›Full record

ArticleChildren (Basel, Switzerland)2022

Improving Recognition of Treatable Rare Neuromuscular Disorders in Primary Care: A Pilot Feasibility Study.

Federica S Ricci, Rossella D'Alessandro, Martina Vacchetti, Anna Salvalaggio, Alessandra Somà, Giorgia Daffunchio, Marco Spada, Renato Turra, Marisa Bobbio, Alessandro Ciuti and 3 more

Abstract read
In one paragraph

Article in Children (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Federica S RicciDivision of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0003-2019-612X
Rossella D'AlessandroDivision of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0002-6358-5937
Martina VacchettiDivision of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.
Anna SalvalaggioDivision of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.
Alessandra SomàDivision of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.
Giorgia DaffunchioDivision of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.
Marco SpadaDivision of Pediatrics, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.
Renato TurraDivision of Primary Care Pediatrics, Health District ASL TO4, Via Po 11, 10034 Turin, Italy.
Marisa BobbioDivision of Primary Care Pediatrics, Health District ASL TO5, Piazza Silvio Pellico 1, 10023 Turin, Italy.
Alessandro CiutiDivision of Child and Adolescent Neuropsychiatry, Health District ASL TO5, Piazza Silvio Pellico 1, 10023 Turin, Italy.
Chiara DavicoDivision of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0003-4378-8419
Benedetto VitielloDivision of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0002-8093-7383
Tiziana E MonginiDivision of Neurology 1, Department of Neuroscience, University of Turin, 10126 Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Innovative targeted treatments for neuromuscular disorders (NMDs) can dramatically improve the course of illness. Diagnostic delay, however, is a major impediment. Here, we present a pilot project aimed at assessing the feasibility of a screening program to identify children at high risk for NMDs within the first 30 months of life. The Promoting Early Diagnosis for Neuromuscular Disorders (PEDINE) project implemented a three-step sequential screening in an area of about 300,000 people with (1) an assessment of the motor development milestones to identify "red flags" for NMDs by primary care pediatricians (PCPs) as part of the routine Health Status Check visits; (2) for the children who screened positive, a community neuropsychiatric assessment, with further referral of suspected NMD cases to (3) a hospital-based specialized tertiary care center. In the first-year feasibility study, a total of 10,032 PCP visits were conducted, and twenty children (0.2% of the total Health Status Check visits) screened positive and were referred to the community neuropsychiatrist. Of these, four had elevated creatine kinase (CK) serum levels. This pilot study shows that screening for NMDs in primary care settings is feasible and allows children at high risk for muscular disorder to be promptly identified.

Indexed as

disease modifying treatmentsearly diagnosismotor development milestonesneuromuscular disordersprimary care pediatricianspublic healthscreening

Identifiers

PMID35884047
PMCPMC9317909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.